Hindustan Bio Sciences Ltd
₹ 8.10
0.00%
19 Apr
- close price
About
Incorporated in 2000, Hindustan Biosciences Limited is engaged in the manufacturing and sale of pharmaceutical products.
Key Points
- Market Cap ₹ 8.30 Cr.
- Current Price ₹ 8.10
- High / Low ₹ 15.2 / 5.15
- Stock P/E 277
- Book Value ₹ 0.67
- Dividend Yield 0.00 %
- ROCE -1.30 %
- ROE -5.19 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 12.0 times its book value
- The company has delivered a poor sales growth of -2.23% over past five years.
- Promoter holding is low: 12.2%
- Company has a low return on equity of -41.8% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 179 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.71 | 3.89 | 2.25 | 0.75 | 1.26 | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 0.97 | |
2.51 | 4.32 | 2.96 | 1.97 | 1.38 | 1.48 | 3.38 | 3.43 | 1.80 | 1.97 | 0.94 | 0.95 | 0.95 | |
Operating Profit | 0.20 | -0.43 | -0.71 | -1.22 | -0.12 | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.02 |
OPM % | 7.38% | -11.05% | -31.56% | -162.67% | -9.52% | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 2.06% |
0.00 | 0.00 | -0.04 | -0.01 | -1.92 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | |
Interest | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.26 | 0.27 | 0.22 | 0.18 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
Profit before tax | -0.08 | -0.72 | -1.00 | -1.44 | -2.08 | -0.49 | -2.27 | 0.11 | 0.12 | -0.96 | -0.51 | -0.04 | 0.04 |
Tax % | 0.00% | 0.00% | 0.00% | -0.69% | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% | 2.08% | 0.00% | 0.00% | |
-0.09 | -0.72 | -0.99 | -1.46 | -2.09 | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.03 | |
EPS in Rs | -0.09 | -0.70 | -0.97 | -1.42 | -2.04 | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.03 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -13% |
5 Years: | -2% |
3 Years: | -22% |
TTM: | 64% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 15% |
3 Years: | % |
TTM: | 107% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 54% |
3 Years: | 42% |
1 Year: | 52% |
Return on Equity | |
---|---|
10 Years: | -17% |
5 Years: | -17% |
3 Years: | -42% |
Last Year: | -5% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 |
Reserves | -0.12 | -0.84 | -1.83 | -3.34 | -5.43 | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.36 |
0.15 | 0.17 | 0.77 | 0.97 | 0.94 | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.59 | |
0.20 | 0.64 | 0.48 | 0.17 | 0.12 | 0.24 | 0.09 | 0.10 | 0.71 | 0.32 | 0.02 | 0.08 | 0.02 | |
Total Liabilities | 10.48 | 10.22 | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.30 |
2.22 | 0.29 | 0.16 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | |
CWIP | 0.00 | 1.92 | 1.92 | 1.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
8.26 | 8.01 | 7.59 | 6.05 | 5.81 | 5.81 | 3.65 | 5.57 | 5.50 | 3.44 | 2.94 | 3.26 | 3.27 | |
Total Assets | 10.48 | 10.22 | 9.67 | 8.05 | 5.88 | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.30 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.34 | 0.04 | -0.46 | -0.27 | 0.46 | -0.16 | -0.23 | -1.32 | 0.82 | 0.75 | -0.34 | -0.05 | |
-0.08 | -0.04 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.00 | -0.01 | 0.51 | 0.30 | -0.63 | 0.18 | 0.21 | 1.50 | -0.81 | -0.93 | 0.34 | 0.05 | |
Net Cash Flow | -0.42 | -0.01 | 0.09 | 0.03 | -0.17 | 0.01 | -0.02 | 0.17 | 0.01 | -0.18 | -0.01 | 0.00 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 72.73 | 138.87 | 202.78 | 155.73 | 136.15 | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 |
Inventory Days | 0.00 | 53.06 | 36.08 | 25.08 | 0.00 | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 |
Days Payable | 78.79 | 84.88 | 39.01 | 44.82 | 7.58 | 185.31 | ||||||
Cash Conversion Cycle | 72.73 | 113.14 | 153.97 | 141.80 | 136.15 | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 |
Working Capital Days | 145.46 | 170.77 | 209.27 | 111.93 | 104.29 | 79.50 | 116.94 | 176.35 | 261.52 | 251.60 | 424.42 | 301.52 |
ROCE % | -0.58% | -7.05% | -9.91% | -16.40% | -1.91% | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% |
Documents
Announcements
- Reg. 40(10) PCS Certificate For The Year Ended 31-03-2024 1d
- Compliance Certificate U/R 7(3) For The Year Ended 31-03-2024 12 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr
- Non-Applicability Of Criteria Of Large Corporate - Initial Disclosure 6 Apr
- Closure of Trading Window 30 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:[1]
a) Tablets
b) Capsules
c) Eye/Ear/Nasal Drops
d) Dry and Liquid Injectables
e) Liquid/Dry Syrups
f) Pre-Filled Syringes
g) Non Sterile/Sterile Ointments